Secukinumab Treatment in Patients With Hidradenitis Suppurativa in Real-World Clinical Settings: A Multicenter Study
Introduction: Treatment of hidradenitis suppurativa (HS) remains a challenge in clinical practice for dermatologists. Although the efficacy and safety of secukinumab (SEC) in the treatment of HS has been demonstrated in phase III studies, real-world data is limited. Objectives: We conducted a ret...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Mattioli1885
2025-01-01
|
| Series: | Dermatology Practical & Conceptual |
| Subjects: | |
| Online Access: | https://dpcj.org/index.php/dpc/article/view/4915 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Introduction: Treatment of hidradenitis suppurativa (HS) remains a challenge in clinical practice for dermatologists. Although the efficacy and safety of secukinumab (SEC) in the treatment of HS has been demonstrated in phase III studies, real-world data is limited.
Objectives: We conducted a retrospective multicenter study to evaluate the efficacy and safety of SEC treatment in HS patients in real-world settings.
Methods: Adult patients who were diagnosed with HS and used SEC for at least 3 months were included in the study.
Results: A total of 31 patients were included in the study; 14 of them (45.2%) were female. The mean age was 39.32 ± 10.26 years, and the mean disease duration was 11.77 ± 7.99 years. Nine (29%) patients were biologic-naive and 10 (32.3%) were adalimumab-naive. Disease severity was Hurley I in 7 patients (22.6%), Hurley II in 9 patients (29%), and Hurley III in 15 patients (48.4%). The Hidradenitis Suppurativa Clinical Response (HiSCR) was achieved in 20 patients (64.5%) in the third month of treatment. SEC treatment was discontinued due to primary ineffectiveness in 9 (29%) patients, secondary ineffectiveness in 1 (3.2%) patient, adverse effects in 1 (3.2%) patient, and loss of follow-up in 1 (3.2%) patient. Paradoxical pyoderma gangrenosum was observed as an adverse effect in 1 patient that resolved after discontinuing SEC and starting infliximab.
Conclusion: SEC appears to be an effective and safe treatment option for HS, especially when used in the early and mild stages of the disease and in biologic-naive patients.
|
|---|---|
| ISSN: | 2160-9381 |